Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 18/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apafant SCHEMBL29528926 | 1.00 | PTAFR (1.00) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| Apafant SCHEMBL1189235 | 0.95 | PTAFR (0.91) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL9661967 | 0.93 | PTAFR (0.87) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL8487172 | 0.88 | PTAFR (0.78) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL8928418 | 0.87 | PTAFR (0.77) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL10469719 | 0.86 | PTAFR (0.76) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL9421185 | 0.86 | PTAFR (0.75) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL9668954 | 0.85 | PTAFR (0.74) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL9661351 | 0.85 | PTAFR (0.74) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL9667679 | 0.85 | PTAFR (0.74) | PTAFRCYP3A4ALOX15OPRK1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 861 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962797-B2 | POWDER COMPOSITIONS FOR INHALATION | JAGOTEC AG (CH) | 2024-05-29 | — | — | EP | claimed |
| CN-106573048-B | Composition for promoting induction of humoral immunity and vaccine pharmaceutical composition | 日东电工株式会社 | 2021-11-09 | — | — | CN | claimed |
| US-20210093636-A1 | Arylamide compounds and compositions and uses thereof | INNOVATION PHARMACEUTICALS INC. | 2021-04-01 | — | — | US | claimed |
| EP-1962797-B1 | POWDER COMPOSITIONS FOR INHALATION | JAGOTEC AG (CH) | 2020-10-28 | — | — | EP | claimed |
| US-20190314370-A1 | Arylamide compounds and compositions and uses thereof | POLYMEDIX, INC. | 2019-10-17 | — | — | US | claimed |
| CN-109893528-A | Koumine treats the purposes of disorders of lipid metabolism and its related disease or illness | 福建医科大学 | 2019-06-18 | — | — | CN | claimed |
| EP-3354263-A1 | DRY POWDER FORMULATIONS | Jagotec AG (CH) | 2018-08-01 | — | — | EP | claimed |
| EP-3275435-A1 | DRY POWDER FORMULATIONS | Jagotec AG (CH) | 2018-01-31 | — | — | EP | claimed |
| EP-1689360-B1 | DRY POWDER FORMULATIONS | JAGOTEC AG (CH) | 2017-08-23 | — | — | EP | claimed |
| US-20160228435-A1 | Arylamide compounds and compositions and uses thereof | INNOVATION PHARMACEUTICALS INC. | 2016-08-11 | — | — | US | claimed |
| WO-2001015677-A2 | USE OF 5-HT1B/1D AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| WO-2001015678-A2 | TOPICAL USE OF KAPPA OPIOID AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-6174878-B1 | OR INTRANASAL COMPOSITION E.G., ASIMADOLINE (EMD-61753), ENADOLINE, BENZENEACETAMIDE, AS AN ANALGESIC FOR EAR INFECTION, SWIMMER'S EAR, ETC.; ACTIVATION OF SPECIFIC RECEPTORS SO NO SIDE EFFECTS | ALCON LABORATORIES, INC. | 2001-01-16 | — | — | US | claimed |
| WO-2000028979-A1 | DRY POWDER FOR INHALATION | JAGO RESEARCH AG (CH) | 2000-05-25 | — | — | WO | claimed |
| US-6015810-A | Aqueous ophthalmic solution containing apafant as active ingredient | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2000-01-18 | — | — | US | claimed |
| EP-0917875-A1 | AQUEOUS EYE DROPS CONTAINING APAFANT AS PRINCIPAL AGENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1999-05-26 | — | — | EP | claimed |
| CN-1199339-A | Aqueous eye drops contg. apafant as principal agent | SANTEN PHARMACEUTICAL CO LTD (JP) | 1998-11-18 | — | — | CN | claimed |
| US-5346894-A | Psychotic disorders, thieno-triazolo-diazepines | KORTH RUTH (DE) | 1994-09-13 | — | — | US | claimed |
| WO-1993020822-A1 | COMPOSITIONS OF PLATELET ACTIVATING FACTOR ANTAGONISTS AND METHODS OF TREATING INTERLEUKIN-2 INDUCED LUNG INJURY THEREWITH | SMITHKLINE BEECHAM CORPORATION (US) | 1993-10-28 | — | — | WO | claimed |
| EP-0369810-A2 | PAF antagonists as anti-hyperendothelinemia agents | Takeda Chemical Industries, Ltd. (JP) | 1990-05-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314370-A1 | Arylamide compounds and compositions and uses thereof | AADAC, AAAS, AHR | PTAFR 3487/4885CYP3A4 3210/4885ALOX15 375/4885 |
| US-20160228435-A1 | Arylamide compounds and compositions and uses thereof | AADAC, AAAS, AHR | PTAFR 3487/4885CYP3A4 3210/4885ALOX15 375/4885 |
| US-20210093636-A1 | Arylamide compounds and compositions and uses thereof | AADAC, AAAS, AHR | PTAFR 3487/4885CYP3A4 3210/4885ALOX15 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.